Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 17/20 | 0.34 |
| ▸ | TP53 | P04637 | 10/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992880 | 0.92 | CYP1A2 (0.32) | MDM2 | |
| SCHEMBL30224188 | 0.92 | CYP1A2 (0.32) | MDM2 | |
| SCHEMBL23994383 | 0.89 | MDM2 (0.33) | MDM2TP53KDM1A | |
| SCHEMBL30224158 | 0.89 | MDM2 (0.33) | MDM2TP53KDM1A | |
| SCHEMBL23994386 | 0.89 | MDM2 (0.33) | MDM2TP53KDM1A | |
| SCHEMBL30181952 | 0.88 | MDM2 (0.34) | MDM2TP53MDM4 | |
| SCHEMBL23993963 | 0.88 | MDM2 (0.34) | MDM2TP53MDM4 | |
| SCHEMBL25005572 | 0.88 | MDM2 (0.35) | MDM2TP53KDM1AMDM4 | |
| SCHEMBL23995047 | 0.88 | MDM2 (0.41) | MDM2TP53MDM4 | |
| SCHEMBL23994162 | 0.86 | MTOR (0.31) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | RIPK1 3077/4885MDM2 2083/4885TP53 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.